Search - tctmd.com

Displaying 121 - 140 of 654

Sort: Relevancy | Date

Presentation TVT 2023

Bioprosthetic Surgical Valves in Intermediate-risk Patients: 1-Year Outcomes of the PARTNER 3 Mitral Valve-in-Valve Study

Presenter: Mayra Guerrero

June 10, 2023

Presentation TVT 2023

Case Presentation 3: Favoring TAVR Explant: When to Throw in the Towel and Operate

Presenter: Keith Allen

June 10, 2023

Presentation TVT 2023

Case Presentation 2: Failed Annular TAVR and ‘How To Do’ TAV-in-TAV (e.g. With BASILICA in Sapien)

Presenter: Jaffar Khan

June 10, 2023

Presentation TVT 2023

Case Presentation 1: Failed Supra-Annular TAVR and ‘How To Do’ TAV-in-TAV (Sapien in Evolut)

Presenter: Sachin Goel

June 10, 2023

Presentation TVT 2023

TAVR Failure Modes, Anatomic Considerations and New Nomenclature for TAV-in-TAV Procedures

Presenter: Gilbert Tang

June 10, 2023

Presentation TVT 2023

Safety and Efficacy of M-TEER in PMR: Insights From the STS/ACC TVT Registry

Presenter: Raj Makkar

June 08, 2023

Presentation TVT 2023

M-TEER Outcomes in Real-World PMR Patients: The PRIME-MR Registry

Presenter: Augustin Coisne

June 08, 2023

Presentation TVT 2023

Contrapoint: M-TEER in Lower Risk PMR Patients: Putting the “Pro” and “Cons” in Perspective

Presenter: Michael Mack

June 08, 2023

Presentation TVT 2023

Results From TAVR Explanation and Redo SAVR are Important Considerations: Updates and Evidence Gaps

Presenter: Basel Ramlawi

June 08, 2023

Presentation TVT 2023

Counterpoint: Not Ready Yet – Ensuring Reproducible ‘Surgical-Like’ Results Needs to be Demonstrated First!

Presenter: Thomas Modine

June 08, 2023

Presentation TVT 2023

Point: Technology Evolution of M-TEER Already Allows the Treatment of Complex Anatomies and Lower Risk Patients!

Presenter: Amar Krishnaswamy

June 08, 2023

Presentation TVT 2023

What Do We Actually Know About Bioprosthetic Valve Durability (SAVR and TAVR)

Presenter: Danny Dvir

June 08, 2023

Presentation TVT 2023

Late-Breaking Clinical Science: Three-Year Outcomes From the Evolut Low Risk TAVR Bicuspid Study

Presenter: Firas Zahr

June 08, 2023

Presentation TVT 2023

SPOTLIGHT LECTURE: Planning for the 2nd Valve Before Placing the First One: Anatomic Considerations in Treating Patients With Long Life Expectancy

Presenter: Janarthanan Sathananthan

June 08, 2023

Presentation TVT 2023

SPOTLIGHT LECTURE: TEER in Primary MR - Clinical Evidence, Indications, and Controversies

Presenter: Charles Davidson

June 08, 2023

Presentation TVT 2023

How Do We Communicate Known vs Uncertain Risks and Benefits of TAVR to Younger (<65 yo) Patients?

Presenter: Sammy Elmariah

June 08, 2023

Presentation TVT 2023

Putting “Lifetime” Into Perspective (How Long Do Patients With AS / AVR Actually Survive)

Presenter: Michael Mack

June 08, 2023

Presentation TCT 2022

Cardiac Damage and Quality of Life After Aortic Valve Replacement: Results From the PARTNER Trials

Presenter: Philippe Genereux

September 18, 2022

Presentation Interventional Complications 2022

How to Build a High risk Program in a Challenging Environment (Difficult Admin, Partners, Surgeons, Geographic Location)

Presenter: Steve Marso

July 15, 2022

Presentation TCT 2021

PARTNER 3: Two-Year Economic Outcomes From a Randomized Trial of TAVR vs. SAVR in Patients at Low Surgical Risk

Presenter: David Cohen

November 05, 2021

Advertisement

Bioprosthetic Surgical Valves in Intermediate-risk Patients: 1-Year Outcomes of the PARTNER 3 Mitral Valve-in-Valve Study

Case Presentation 3: Favoring TAVR Explant: When to Throw in the Towel and Operate

Case Presentation 2: Failed Annular TAVR and ‘How To Do’ TAV-in-TAV (e.g. With BASILICA in Sapien)

Case Presentation 1: Failed Supra-Annular TAVR and ‘How To Do’ TAV-in-TAV (Sapien in Evolut)

TAVR Failure Modes, Anatomic Considerations and New Nomenclature for TAV-in-TAV Procedures

Safety and Efficacy of M-TEER in PMR: Insights From the STS/ACC TVT Registry

M-TEER Outcomes in Real-World PMR Patients: The PRIME-MR Registry

Contrapoint: M-TEER in Lower Risk PMR Patients: Putting the “Pro” and “Cons” in Perspective

Results From TAVR Explanation and Redo SAVR are Important Considerations: Updates and Evidence Gaps

Counterpoint: Not Ready Yet – Ensuring Reproducible ‘Surgical-Like’ Results Needs to be Demonstrated First!

Point: Technology Evolution of M-TEER Already Allows the Treatment of Complex Anatomies and Lower Risk Patients!

What Do We Actually Know About Bioprosthetic Valve Durability (SAVR and TAVR)

Late-Breaking Clinical Science: Three-Year Outcomes From the Evolut Low Risk TAVR Bicuspid Study

SPOTLIGHT LECTURE: Planning for the 2nd Valve Before Placing the First One: Anatomic Considerations in Treating Patients With Long Life Expectancy

SPOTLIGHT LECTURE: TEER in Primary MR - Clinical Evidence, Indications, and Controversies

How Do We Communicate Known vs Uncertain Risks and Benefits of TAVR to Younger (<65 yo) Patients?

Putting “Lifetime” Into Perspective (How Long Do Patients With AS / AVR Actually Survive)

Cardiac Damage and Quality of Life After Aortic Valve Replacement: Results From the PARTNER Trials

How to Build a High risk Program in a Challenging Environment (Difficult Admin, Partners, Surgeons, Geographic Location)

PARTNER 3: Two-Year Economic Outcomes From a Randomized Trial of TAVR vs. SAVR in Patients at Low Surgical Risk

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content